146533-34-8

Basic information

• Product Name: Pyrimidine, 4,6-dichloro-5-[4-(1-methylethyl)phenyl]-
• CAS NO: 146533-34-8
• Molecular Formula: C13H12Cl2N2
• Molecular Weight: 267.158
• Mol File: 146533-34-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Pyrimidine, 4,6-dichloro-5-[4-(1-methylethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 4,6-dichloro-5-[4-(1-methylethyl)phenyl]-(146533-34-8)
• EPA Substance Registry System: Pyrimidine, 4,6-dichloro-5-[4-(1-methylethyl)phenyl]-(146533-34-8)

Safety Data

• Hazardous Substances Data: 146533-34-8(Hazardous Substances Data)

Upstream product

• 926008-55-1 5-(4-isopropylphenyl)pyrimidine-4,6-diol 
• 14062-21-6 (4-isopropylphenyl)acetic acid ethyl ester 
• 4476-28-2 (4-isopropylphenyl)acetic acid 
• 97621-10-8 2-(4-isopropylphenyl)malonic acid diethyl ester 
• 1267356-14-8 C₁₄H₁₈O₄ 

Downstream Products

• 926008-75-5 {4-[6-chloro-5-(4-isopropylphenyl)pyrimidin-4-ylethynyl]phenyl}dimethylamine 
• 1393813-59-6 C₂₆H₂₇BrN₆O₄S 

Relevant articles and documents

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

Sulfonamides and uses

Sulfonamides of formula I, in which the symbols R1 -R6, X, Y and n have the significance given in the description and which are in part novel compounds, and salts thereof, which can be used as active ingredients for the manufacture of medicaments for the treatment of circulatory disorders, especially hypertension, ischemia, vasospasms and angina pectoris, are described.